Search

everythinglearnresearchcommunity

for

Search:↓

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

Older patients sticking to their prostate medication saw lasting health benefits.

Dutasteride improved both hair loss and acne in two young men.